Physiological and pathophysiological characteristics of ataxin-3 isoforms

Ataxin-3 is a deubiquitinating enzyme and the affected protein in the neurodegenerative disorder Machado–Joseph disease (MJD). The ATXN3 gene is alternatively spliced, resulting in protein isoforms that differ in the number of ubiquitin-interacting motifs. Additionally, nonsynonymous SNPs in ATXN3 cause amino acid changes in ataxin-3, and one of these polymorphisms introduces a premature stop codon in one isoform. Here, we examined the effects of different ataxin-3 isoforms and of the premature stop codon on ataxin-3's physiological function and on main disease mechanisms. At the physiological level, we show that alternative splicing and the premature stop codon alter ataxin-3 stability and that ataxin-3 isoforms differ in their enzymatic deubiquitination activity, subcellular distribution, and interaction with other proteins. At the pathological level, we found that the expansion of the polyglutamine repeat leads to a stabilization of ataxin-3 and that ataxin-3 isoforms differ in their aggregation properties. Interestingly, we observed a functional interaction between normal and polyglutamine-expanded ATXN3 allelic variants. We found that interactions between different ATXN3 allelic variants modify the physiological and pathophysiological properties of ataxin-3. Our findings indicate that alternative splicing and interactions between different ataxin-3 isoforms affect not only major aspects of ataxin-3 function but also MJD pathogenesis. Our results stress the importance of considering isoforms of disease-causing proteins and their interplay with the normal allelic variant as disease modifiers in MJD and autosomal-dominantly inherited diseases in general.

[1]  R. Krüger,et al.  Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3 , 2018, Front. Mol. Neurosci..

[2]  I. M. Martins,et al.  Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3 , 2018, Proceedings of the National Academy of Sciences.

[3]  R. Hartmann-Petersen,et al.  Polyglutamine expansion of ataxin-3 alters its degree of ubiquitination and phosphorylation at specific sites , 2017, Neurochemistry International.

[4]  C. Carlson,et al.  A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3 , 2017, Brain : a journal of neurology.

[5]  H. Paulson,et al.  Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3 , 2017, Human molecular genetics.

[6]  Kara Dolinski,et al.  The BioGRID interaction database: 2017 update , 2016, Nucleic Acids Res..

[7]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[8]  S. Gygi,et al.  mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy , 2015, Proceedings of the National Academy of Sciences.

[9]  Sokol V. Todi,et al.  The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster , 2015, Neurobiology of Disease.

[10]  H. Paulson,et al.  A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript. , 2015, Human molecular genetics.

[11]  Karolina A Majorek,et al.  Double trouble—Buffer selection and His‐tag presence may be responsible for nonreproducibility of biomedical experiments , 2014, Protein science : a publication of the Protein Society.

[12]  Sokol V. Todi,et al.  Using membrane‐targeted green fluorescent protein to monitor neurotoxic protein‐dependent degeneration of Drosophila eyes , 2014, Journal of neuroscience research.

[13]  K. Scaglione,et al.  Ubiquitin-Binding Site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23 , 2014, Nature Communications.

[14]  N. Mizushima,et al.  Cycloheximide inhibits starvation-induced autophagy through mTORC1 activation. , 2014, Biochemical and biophysical research communications.

[15]  K. Scaglione,et al.  Ubiquitination Regulates the Neuroprotective Function of the Deubiquitinase Ataxin-3 in Vivo* , 2013, The Journal of Biological Chemistry.

[16]  R. Montiel,et al.  Transcript Diversity of Machado–Joseph Disease Gene (ATXN3) Is Not Directly Determined by SNPs in Exonic or Flanking Intronic Regions , 2013, Journal of Molecular Neuroscience.

[17]  Duhee Bang,et al.  A library of TAL effector nucleases spanning the human genome , 2013, Nature Biotechnology.

[18]  C. Richter,et al.  Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). , 2013, Human molecular genetics.

[19]  K. Xia,et al.  SUMO-1 Modification on K166 of PolyQ-Expanded aTaxin-3 Strengthens Its Stability and Increases Its Cytotoxicity , 2013, PloS one.

[20]  Beatriz Alvarez-Castelao,et al.  A Critical Appraisal of Quantitative Studies of Protein Degradation in the Framework of Cellular Proteostasis , 2012, Biochemistry research international.

[21]  Andrei L. Turinsky,et al.  A Census of Human Soluble Protein Complexes , 2012, Cell.

[22]  H. Paulson,et al.  Toward understanding Machado–Joseph disease , 2012, Progress in Neurobiology.

[23]  J. D. Mills,et al.  Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases , 2012, Neurobiology of Aging.

[24]  J. Mertens,et al.  Excitation-induced ataxin-3 aggregation in neurons from patients with Machado–Joseph disease , 2011, Nature.

[25]  Jin-Soo Kim,et al.  Surrogate reporters for enrichment of cells with nuclease-induced mutations , 2011, Nature Methods.

[26]  C. Crochemore,et al.  Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model , 2011, Journal of neurochemistry.

[27]  K. Riabowol,et al.  REAP: A two minute cell fractionation method , 2010, BMC Research Notes.

[28]  H. Paulson,et al.  Splice Isoforms of the Polyglutamine Disease Protein Ataxin-3 Exhibit Similar Enzymatic yet Different Aggregation Properties , 2010, PloS one.

[29]  R. Montiel,et al.  The (CAG)n tract of Machado–Joseph Disease gene (ATXN3): a comparison between DNA and mRNA in patients and controls , 2010, European Journal of Human Genetics.

[30]  R. Montiel,et al.  Increased transcript diversity: novel splicing variants of Machado–Joseph Disease gene (ATXN3) , 2010, neurogenetics.

[31]  O. Riess,et al.  Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models , 2010, Neurobiology of Disease.

[32]  Wolfgang Huber,et al.  EBImage—an R package for image processing with applications to cellular phenotypes , 2010, Bioinform..

[33]  Hartwig Wolburg,et al.  Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. , 2009, Human molecular genetics.

[34]  O. Riess,et al.  Identification and functional dissection of localization signals within ataxin-3 , 2009, Neurobiology of Disease.

[35]  B. Evert,et al.  CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. , 2009, Human molecular genetics.

[36]  H. Paulson,et al.  Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin‐3 , 2009, The EMBO journal.

[37]  H. Paulson,et al.  The Deubiquitinating Enzyme Ataxin-3, a Polyglutamine Disease Protein, Edits Lys63 Linkages in Mixed Linkage Ubiquitin Chains* , 2008, Journal of Biological Chemistry.

[38]  D. Timmann,et al.  Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6 , 2008, Movement disorders : official journal of the Movement Disorder Society.

[39]  M. Valtorta,et al.  Study of subcellular localization and proteolysis of ataxin-3 , 2008, Neurobiology of Disease.

[40]  Janghoo Lim,et al.  Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1 , 2008, Nature.

[41]  R. Roepman,et al.  A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes , 2007, Proteomics.

[42]  T. Klockgether,et al.  Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. , 2007, Biochemical and biophysical research communications.

[43]  H. Paulson,et al.  Cellular Turnover of the Polyglutamine Disease Protein Ataxin-3 Is Regulated by Its Catalytic Activity* , 2007, Journal of Biological Chemistry.

[44]  P. Breuer,et al.  Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes , 2007, Biological chemistry.

[45]  L. Rüttiger,et al.  Nuclear Localization of Ataxin-3 Is Required for the Manifestation of Symptoms in SCA3: In Vivo Evidence , 2007, The Journal of Neuroscience.

[46]  G. Lederkremer,et al.  Transient arrest in proteasomal degradation during inhibition of translation in the unfolded protein response. , 2007, The Biochemical journal.

[47]  Tao Zhang,et al.  p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin‐3 to the proteasome , 2007, Journal of neurochemistry.

[48]  D. Geschwind,et al.  Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado‐Joseph disease protein ataxin‐3 , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  T. Klockgether,et al.  Ataxin-3 Represses Transcription via Chromatin Binding, Interaction with Histone Deacetylase 3, and Histone Deacetylation , 2006, The Journal of Neuroscience.

[50]  M. Valtorta,et al.  Ataxin‐3 is subject to autolytic cleavage , 2006, The FEBS journal.

[51]  K. Beyer α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers , 2006, Acta Neuropathologica.

[52]  V. Wong,et al.  A multistep mutation mechanism drives the evolution of the CAG repeat at MJD/SCA3 locus , 2006, European Journal of Human Genetics.

[53]  F. Hartl,et al.  Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. , 2006, Human molecular genetics.

[54]  R. Montiel,et al.  Population Genetics of Wild-Type CAG Repeats in the Machado-Joseph Disease Gene in Portugal , 2006, Human Heredity.

[55]  Elena Cattaneo,et al.  Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. , 2005, Pharmacological research.

[56]  H. Paulson,et al.  Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. , 2005, Molecular cell.

[57]  H. Hendriks,et al.  Age at onset variance analysis in spinocerebellar ataxias: A study in a Dutch–French cohort , 2005, Annals of neurology.

[58]  H. Zoghbi,et al.  The Effects of the Polyglutamine Repeat Protein Ataxin-1 on the UbL-UBA Protein A1Up* , 2004, Journal of Biological Chemistry.

[59]  Manuela M. Santos,et al.  Genomic structure, promoter activity, and developmental expression of the mouse homologue of the Machado-Joseph disease (MJD) gene. , 2004, Genomics.

[60]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[61]  D. Wolf,et al.  A genomic screen identifies Dsk2p and Rad23p as essential components of ER‐associated degradation , 2004, EMBO reports.

[62]  S. Grossman,et al.  A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway , 2004, Oncogene.

[63]  P. Leigh,et al.  Degradation properties of polyglutamine-expanded human androgen receptor in transfected cells , 2004, Neuroscience Letters.

[64]  H. Ishimoto,et al.  Molecular clearance of ataxin‐3 is regulated by a mammalian E4 , 2004, The EMBO journal.

[65]  Barrington G. Burnett,et al.  The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. , 2003, Human molecular genetics.

[66]  P. Lockhart,et al.  Functional association of the parkin gene promoter with idiopathic Parkinson's disease. , 2002, Human molecular genetics.

[67]  A. Krainer,et al.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.

[68]  H. Kampinga,et al.  Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. , 2002, Human molecular genetics.

[69]  G. Rouleau,et al.  Improvement in the molecular diagnosis of Machado-Joseph disease. , 2001, Archives of neurology.

[70]  Hangil Park,et al.  Identification of proteins that interact with mammalian peptide:N-glycanase and implicate this hydrolase in the proteasome-dependent pathway for protein degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Hattori,et al.  The genomic structure and expression of MJD, the Machado-Joseph disease gene , 2001, Journal of Human Genetics.

[72]  Í. Lopes-Cendes,et al.  Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. , 2001, American journal of human genetics.

[73]  C. Morris,et al.  Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation. , 2000, Brain : a journal of neurology.

[74]  J. Hardy,et al.  Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion. , 1999, Human molecular genetics.

[75]  Osamu Hori,et al.  A Novel Presenilin‐2 Splice Variant in Human Alzheimer's Disease Brain Tissue , 1999, Journal of neurochemistry.

[76]  G. Schellenberg,et al.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[77]  S. Pulst,et al.  Expression of ataxin‐2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2 , 1999, Annals of neurology.

[78]  Í. Lopes-Cendes,et al.  Study of three intragenic polymorphisms in the Machado-Joseph disease gene (MJD1) in relation to genetic instability of the (CAG)n tract , 1999, European Journal of Human Genetics.

[79]  E. Hirsch,et al.  Heterogeneous Intracellular Localization and Expression of Ataxin-3 , 1998, Neurobiology of Disease.

[80]  T. Klockgether,et al.  An Isoform of Ataxin‐3 Accumulates in the Nucleus of Neuronal Cells in Affected Brain Regions of SCA3 Patients , 1998, Brain pathology.

[81]  Fumiaki Tanaka,et al.  Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy , 1998, Annals of neurology.

[82]  Nancy M Bonini,et al.  Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in Drosophila , 1998, Cell.

[83]  A Dürr,et al.  Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. , 1998, Human molecular genetics.

[84]  Dale E. Bredesen,et al.  Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract* , 1998, The Journal of Biological Chemistry.

[85]  S. W. Davies,et al.  Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.

[86]  H. Zoghbi,et al.  Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures , 1997, Nature.

[87]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[88]  Masahiko Watanabe,et al.  Machado–Joseph disease gene products carrying different carboxyl termini , 1997, Neuroscience Research.

[89]  K. Fischbeck,et al.  Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3 , 1997, Neuron.

[90]  K. Fischbeck,et al.  Machado‐Joseph disease gene product is a cytoplasmic protein widely expressed in brain , 1997, Annals of neurology.

[91]  L. Cupples,et al.  A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. , 1996, American journal of human genetics.

[92]  S. Narumiya,et al.  Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo , 1996, Nature Genetics.

[93]  Alexandra Durr,et al.  Spinocerebellar ataxia 3 and machado‐joseph disease: Clinical, molecular, and neuropathological features , 1996, Annals of neurology.

[94]  L Junck,et al.  Machado-Joseph disease and SCA3 , 1996, Neurology.

[95]  Í. Lopes-Cendes,et al.  Correlation between CAG repeat length and clinical features in Machado-Joseph disease. , 1995, American journal of human genetics.

[96]  L. Schöls,et al.  Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients. , 1995, Human molecular genetics.

[97]  W. Brown,et al.  Inhibition of protein synthesis separates autophagic sequestration from the delivery of lysosomal enzymes. , 1993, Journal of cell science.

[98]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[99]  R. A. Crowther,et al.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease , 1989, Neuron.

[100]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[101]  Thomas M. Durcan,et al.  The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. , 2011, Human molecular genetics.

[102]  Jürgen Cox,et al.  A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics , 2009, Nature Protocols.

[103]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[104]  Yi Zhang,et al.  Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. , 2003, Molecular cell.

[105]  Shigenobu Nakamura,et al.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 , 1994, Nature Genetics.

[106]  E. Fellinger,et al.  Occurrence and inhibition by cycloheximide of apoptosis in vinblastine-treated murine pancreas. A role for autophagy? , 1991, Acta biologica Hungarica.

[107]  T. Papadopoulos,et al.  Regression of rat liver autophagic vacuoles by locally applied cycloheximide. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[108]  J. Kovács Effect of cycloheximide on induced autophagy in epithelial cells of the seminal vesicle of mice. , 1974, Acta morphologica Academiae Scientiarum Hungaricae.